The rapidly evolving primary care market and the growing influence of managed care add interesting wrinkles to the US market debut of Ironwood Pharmaceutical Inc.’s constipation drug Linzess (linaclotide).
The once-daily oral drug received FDA approval on August 30 for chronic idiopathic constipation and irritable bowel syndrome with constipation...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?